Key Highlights

  • Cytek Biosciences (NASDAQ:CTKB) appears on the aggressive small cap screen with a one-year EPS change of 506.68% and a Market Value of about USD 732 million, at USD 5.62 in the November 13 snapshot, near its 52-week high of USD 6.34.
  • Third quarter Revenue rose 2% to USD 53.2 million, with service revenue up about 13%, and GAAP gross Margin improved to 59% from 53%.
  • The net loss was USD 6.1 million, or USD 0.05 per share, against USD 5.5 million a year earlier, and the shares fell about 8.2% after the release.
  • Cash, restricted cash and marketable securities of USD 256.3 million and almost no Debt support the business, while 2026 revenue guidance was narrowed to USD 208 million to USD 211 million.

What the Quarter Showed

Cytek, which makes full spectrum flow cytometry instruments used in immunology and cell biology research, reported on November 4. Revenue was USD 53.2 million against USD 52.3 million a year earlier. Product revenue slipped to about USD 37.2 million, while service revenue rose to about USD 16.1 million, and Recurring Revenue from service and reagents reached USD 19.1 million, or 36% of trailing revenue against 33%. US revenue grew 12% and revenue from high end instruments rose 11%, with placements of the newer Aurora Evo system nearly doubling. The installed base reached 4,073 after 140 additions in the quarter. GAAP gross margin rose to 59% from 53%, and adjusted gross margin reached 61%. Operating expenses rose 8% to USD 39.6 million, with general and administrative costs up 14% largely because of litigation, which left an operating loss of USD 8.4 million against USD 9.2 million.

Reading the Screen Figure

The one-year EPS change of 506.68% on the screen should be treated with caution. Cytek is not consistently profitable: the third quarter net loss was USD 6.1 million, or USD 0.05 per share, slightly wider than a year earlier, and the nine-month loss was USD 37.1 million, or USD 0.29 per share. Adjusted EBITDA was USD 0.7 million, down from USD 2.5 million. The screen figure likely compares small numbers near zero and is not a reliable growth signal. The Balance Sheet is the stronger part of the story. Cash, restricted cash and marketable securities totalled USD 256.3 million at September 30, down only USD 5.7 million from June, and Funded Debt is negligible. Investors should also note a Patent dispute. In August, a Jury found for Cytek on three of four claims but found infringement on the fourth, with damages of about USD 56 million, and post-verdict motions are pending.

Outlook and Catalysts

Cytek narrowed its 2026 revenue guidance to USD 208 million to USD 211 million from USD 207 million to USD 212 million, keeping the midpoint. That implies fourth quarter revenue of roughly USD 57 million to USD 60 million, the seasonally strongest period for instrument sales as research budgets are spent before year end. The key drivers are academic and government funding in the United States, Demand from biopharma customers, and adoption of Aurora Evo and the new Borealis platform. A collaboration with a large European diagnostics distributor announced in September could broaden clinical reach, and a cloud analysis product launched the same month adds software revenue. Risks include pressure on US research grants, China exposure, the outcome of the patent appeal and continued legal costs. Investors will look for gross margin to stay near 60% and for operating expenses to fall as litigation winds down.

Where Things Stand

Cytek Biosciences (NASDAQ:CTKB) is improving gross margin and growing recurring revenue, but it still posts small losses, so the screen's EPS growth is not a dependable signal. A strong cash position supports the Business while the patent dispute and research funding remain the main uncertainties into 2027.